

2740438

To: (10)(2e) (10)(2e) @minvws.nl; 5.1.2e (10)(2e) @minvws.nl
From: 5.1.2e
Sent: Wed 7/15/2020 8:55:39 AM
Subject: RE: Astra Zeneca

We hebben het gisteren met (10)(2e) besproken, die was hoopvol dat het deze week afgerond zou kunnen worden. Laten we maar even rustig wachten.

Groet,
 5.1.2e

Van: (10)(2e) <(10)(2e) @minvws.nl>
Verzonden: woensdag 15 juli 2020 10:37
Aan: 5.1.2e <(10)(2e) @minvws.nl>; 5.1.2e <(10)(2e) @minvws.nl>
Onderwerp: FW: Astra Zeneca

Hallo 5.1.2e

(10)(2a)

(10)(2a)

Ik laat het even aan jullie of we nog extra signalen aan EC/DUI willen geven en doe hier verder zelf even niets mee.

Groet, (10)(2a)

Van: (10)(2e) <(10)(2e) @astrazeneca.com>
Verzonden: woensdag 15 juli 2020 10:19
Aan: (10)(2e) <(10)(2e) @minvws.nl>
Onderwerp: Fwd: Astra Zeneca

FYI

Sent from my iPhone
 Begin forwarded message:

From: (10)(2e) 5.1.2e (10)(2e) @bmg.bund.de>
Date: 15 July 2020 at 09:38:50 CEST
To: (10)(2e) <(10)(2e) @astrazeneca.com>
Cc: "Spahn, Jens -Minister BMG" <(10)(2e) @bmg.bund.de>, (10)(2e) BMG" <(10)(2e) @bmg.bund.de>, "5.1.2e (10)(2e) (10)(2e) @bmg.bund.de>, (10)(2e) 5.1.2e (10)(2e) @astrazeneca.com>, (10)(2e) @ec.europa.eu" <(10)(2e) @ec.europa.eu>
Subject: AW: Astra Zeneca

Dear Mr (10)(2e)

we appreciate your update on the interaction with the Commission. Minister Spahn follows the AstraZeneca vaccine contract very closely and has regular meetings on progress with the European Commissioner for Health, Stella Kyriakides, and with European Health Ministers. In the last meeting on Monday this week, the time schedule we agreed on was to solve this week last legal hurdles, present the contract to the steering board and sign until end of this week.

2740438

Sincerely, (10)(2e)

Mit freundlichen Grüßen
Im Auftrag

(10)(2e)

Leiter der Abteilung 1 „Arzneimittel, Medizinprodukte und Biotechnologie“
Bundesministerium für Gesundheit

Friedrichstraße 108, 10117 Berlin

Postanschrift: 11055 Berlin

(10)(2e)

(10)(2e)

(10)(2e) @bmg.bund.de

www.bundesgesundheitsministerium.de

www.twitter.com/BMG_Bund

www.facebook.com/BMG.Bund

Hinweis zu externen Links: Auf Art und Umfang der übertragenen bzw. gespeicherten Daten hat das BMG keinen Einfluss.

Der Schutz Ihrer Daten ist uns wichtig. Nähere Informationen zum Umgang mit personenbezogenen Daten im BMG können Sie der Datenschutzerklärung auf <https://www.bundesgesundheitsministerium.de/datenschutz.html> entnehmen.

-----Ursprüngliche Nachricht-----

Von: (10)(2e) (10)(2e) @astrazeneca.com]

Gesendet: Dienstag, 14. Juli 2020 22:07

An: (10)(2e) 1 BMG <(10)(2e) @bmg.bund.de>

Cc: 5.1.2e -Minister BMG <(10)(2e) @bmg.bund.de>; (10)(2e) BMG
<(10)(2e) @bmg.bund.de>; (10)(2e) BMG <(10)(2e) @bmg.bund.de>; (10)(2e) BMG <(10)(2e) @bmg.bund.de>; (10)(2e) <(10)(2e) @astrazeneca.com>

Betreff: FW: Astra Zeneca

Dear Mr. (10)(2e)

I would like to ask for your attention to the email exchange below. (10)(2a)

(10)(2a) We now understand that the Commission first wants to send us an invite for a 'tender' to which we can supposedly respond with the resubmission of our draft Funding Agreement. I have spoken with Mrs. Gallina on several occasions and understand that they are working hard on this. (10)(2a)

(10)(2a)

(10)(2a) and the second payment deadline is due by next Monday.

2740438

(10)(2a)

I would highly appreciate if you could asap internally discuss this and provide me with your feedback.

Thanking you in advance for your efforts,

With best regards,

(10)(2e)

AstraZeneca GmbH

Tinsdaler Weg 183, 22880 Wedel

(10)(2e)

(10)(2e)

(10)(2e) <[@astrazeneca.com](mailto:(10)(2e)@astrazeneca.com)> <(10)(2e)@astrazeneca.com>

Geschäftsführer: (10)(2e)

Vorsitzender des Aufsichtsrates: (10)(2e)

Handelsregister: AG Pinneberg HRB 5069

From: (10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)> <(10)(2e)@ec.europa.eu>

Sent: 13 July 2020 17:34

To: (10)(2e) <(10)(2e)@astrazeneca.com>

Cc: (10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)>; (10)(2e) <[@bmg.bund.de](mailto:(10)(2e)@bmg.bund.de)>; (10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)>;
(10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)>; (10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)>; (10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)>;
(10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)>

Subject: RE: Astra Zeneca

Dearest (10)(2e),

Indeed and my personal, sincere apologies because time is precious for both of us.

Once the invite is unblocked I hope we shall be on the right path.

Best wishes, s

Dear Sandra,

Several days have again passed since we last spoke on Thursday.

Best regards,

(10)(20)

2740438

AstraZeneca GmbH

Tinsdaler Weg 183, 22880 Wedel

(10)(2e)

(10)(2e)

(10)(2e)

@astrazeneca.com <(10)(2e)@astrazeneca.com>

Geschäftsführer: 5.1.2e (10)(2e)

Vorsitzender des Aufsichtsrates: (10)(2e)

Handelsregister: AG Pinneberg HRB 5069

From: (10)(2e)

Sent: 09 July 2020 11:12

To: (10)(2e) @ec.europa.eu <(10)(2e)@ec.europa.eu>

Cc: (10)(2e) @ec.europa.eu <(10)(2e)@ec.europa.eu>; (10)(2e) @bmg.bund.de

<(10)(2e)@bmg.bund.de>; (10)(2e) @ec.europa.eu

<(10)(2e)@ec.europa.eu>; (10)(2e) @ec.europa.eu

<(10)(2e)@ec.europa.eu>; (10)(2e) @ec.europa.eu

<(10)(2e)@ec.europa.eu>; (10)(2e) @ec.europa.eu

<(10)(2e)@ec.europa.eu>; (10)(2e) @ec.europa.eu <(10)(2e)@ec.europa.eu>

Subject: RE: Astra Zeneca

Dear 5.1.2e

Thanks for our constructive dialogue of last Tuesday. As discussed during the meeting, I would appreciate if we could receive the following at your earliest convenience:

- List of names and functions/positions of the people in your team and attending the call
- Your estimated timing of when the first upfront payment to AstraZeneca can be done (which was due on July 3rd)
- Your response to our Draft Funding Agreement proposal (which you aimed for to get to us by yesterday night)

As indicated during our phone conversation, time is of the essence for us, as we are unable to pre-finance all CMO commitments for this Vaccine production which we are delivering at no-profit. Hence, I would like to remind you that a delay in payment will impact on our ability to deliver the quantities within the timelines indicated. The second third of the upfront payment for the 'Initial Europe Doses' is due on July 20th.

In order to accelerate the possibility for the European Commission to make the advance payments, we are proposing to add a short addendum to the current Term Sheet, indicating that the European Commission will take over the commitments from the Coalition Governments for the Term Sheet and will be the responsible party to agree the Funding Agreement

2740438

with AstraZeneca. I would appreciate your opinion to this proposal.

Please let me also know asap when we can expect your response to the Draft Funding Agreement, so I can prepare and reserve time with my team for this.

Looking forward to your response,

Best regards,

(10)(2e)

(10)(2e)

AstraZeneca GmbH

Tinsdaler Weg 183, 22880 Wedel

(10)(2e)

(10)(2e)

(10)(2e) <[@astrazeneca.com](mailto:(10)(2e)@astrazeneca.com)> <(10)(2e)@astrazeneca.com>

Geschäftsführer: (10)(2e)

Vorsitzender des Aufsichtsrates: (10)(2e)

Handelsregister: AG Pinneberg HRB 5069

From: (10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)> <(10)(2e)@ec.europa.eu> <(10)(2e)@ec.europa.eu>
<(10)(2e)@ec.europa.eu>

Sent: 06 July 2020 22:05

To: (10)(2e) <(10)(2e)@astrazeneca.com> <(10)(2e)@astrazeneca.com>

Cc: (10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)> <(10)(2e)@ec.europa.eu>; (10)(2e) <[@bmg.bund.de](mailto:(10)(2e)@bmg.bund.de)>

<(10)(2e)@bmg.bund.de>; (10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)>

<(10)(2e)@ec.europa.eu>; (10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)>

<(10)(2e)@ec.europa.eu>; (10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)>

<(10)(2e)@ec.europa.eu>; (10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)>

<(10)(2e)@ec.europa.eu>; (10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)>

Subject: RE: Astra Zeneca

2740438

Dear 5.1.2e (10)(2e)

Thank you for your mail. If you are available, we could have a meeting tomorrow at 11:00 or 12:00 as you prefer.

My mobile number is (10)(2e) in case you were to have a problem.

Best regards,

5.1.2e

5.1.2e

<http://ec.europa.eu/trade/images/ec-logo-signature_2012.png>

European Commission

5.1.2e

TRADE.DG1 in charge of Directions B and C

* (10)(2e)

B-1049 Brussels/Belgium

* (10)(2e)

* (10)(2e)

(10)(2e) @ec.europa.eu <(10)(2e) @ec.europa.eu>

<http://ec.europa.eu/trade> <<http://ec.europa.eu/trade>>

From: (10)(2e) <(10)(2e) @astrazeneca.com <(10)(2e) @astrazeneca.com>>

Sent: Monday, July 6, 2020 8:29 AM

To: 5.1.2e (10)(2e) @ec.europa.eu <(10)(2e) @ec.europa.eu>; (10)(2e) (10)(2e) (10)(2e) @ec.europa.eu <(10)(2e) @ec.europa.eu>

Cc: 5.1.2e (10)(2e) @ec.europa.eu <(10)(2e) @ec.europa.eu>; (10)(2e) 5.1.2e (10)(2e) @bmg.bund.de <(10)(2e) @bmg.bund.de>

Subject: RE: Astra Zeneca

Dear 5.1.2e

2740438

(10)(2a)

(10)(2a)

I would very much appreciate to understand how and when you would like to initiate discussions with AstraZeneca, how you would like to handle the financial obligations agreed in the Term Sheet and when we can expect your feedback on our Draft Funding Agreement.

Yours sincerely,

(10)(2e)

AstraZeneca GmbH
Tinsdaler Weg 183, 22880 Wedel

(10)(2e)

(10)(2e)

(10)(2e) <[@astrazeneca.com](mailto:(10)(2e)@astrazeneca.com)> <(10)(2e)@astrazeneca.com>

Geschäftsführer: Dr. (10)(2e)

Vorsitzender des Aufsichtsrates: (10)(2e)

Handelsregister: AG Pinneberg HRB 5069

From: (10)(2e)

Sent: 02 July 2020 21:15

To: (10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)> <(10)(2e)@ec.europa.eu>; (10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)>

Cc: (10)(2e) <[@ec.europa.eu](mailto:(10)(2e)@ec.europa.eu)> <(10)(2e)@ec.europa.eu>

Subject: RE: Astra Zeneca

2740438

Dear 5.1.2e

As lead for the AstraZeneca team re the European Agreement for the supply of our Covid-19 vaccine, I would appreciate to connect with you asap to discuss next steps and estimated timelines. Can we set-up a call tomorrow? Please let me know what time would be most convenient to you.

Looking forward to your response,

Sincerely,

(10)(2e)

AstraZeneca GmbH

Tinsdaler Weg 183, 22880 Wedel

(10)(2e)

(10)(2e)

(10)(2e)

5.1.2e@astrazeneca.com

(10)(2e)

5.1.2e@astrazeneca.com

Geschäftsführer: 5.1.2e (10)(2e)

Vorsitzender des Aufsichtsrates: (10)(2e)

Handelsregister: AG Pinneberg HRB 5069

From: (10)(2e) 5.1.2e (10)(2e) 5.1.2e@bmg.bund.de <(10)(2e) 5.1.2e@bmg.bund.de> >

Sent: 02 July 2020 09:28

To: (10)(2e) 5.1.2e@ec.europa.eu <(10)(2e) 5.1.2e@ec.europa.eu> ; (10)(2e) 5.1.2e@ec.europa.eu <(10)(2e) 5.1.2e@ec.europa.eu>

Cc: (10)(2e) 5.1.2e (10)(2e) 5.1.2e@astrazeneca.com <(10)(2e) 5.1.2e@astrazeneca.com> >; (10)(2e) 5.1.2e@bmg.bund.de <(10)(2e) 5.1.2e@bmg.bund.de> >; (10)(2e) 5.1.2e@ec.europa.eu <(10)(2e) 5.1.2e@ec.europa.eu>

Subject: Astra Zeneca

Dear 5.1.2e dear (10)(2e)

2740438

I would like to introduce to you **[REDACTED]** from Astra Zeneca. He and his team will be the contact for finalizing the "funding agreement" with the Commission as basis for the subsequent first payments to Astra Zeneca.

Minister Spahn has informed yesterday evening CEO Pascal Soriot of Astra Zeneca about that transition.

As lead for the AZ term sheet for the four partners of the (former) inclusive vaccine alliance, Minister Spahn and our team will be available to support that work. We think that Astra Zeneca offers (dataset of today) a very promising vaccine candidate with positive progress of the clinical development and a reasonable business plan.

Sincerely, **[REDACTED]**

Mit freundlichen Grüßen
Im Auftrag

[REDACTED]

Leiter der Abteilung 1 „Arzneimittel, Medizinprodukte und Biotechnologie“
Bundesministerium für Gesundheit

Friedrichstraße 108, 10117 Berlin

Postanschrift: 11055 Berlin

[REDACTED]

[REDACTED]

[REDACTED] @bmg.bund.de <**[REDACTED]** @bmg.bund.de>

www.bundesgesundheitsministerium.de

<[https://urldefense.com/v3/_http://www.bundesgesundheitsministerium.de_!!DOxrgLBm!WBVrxOK16DCealygIMCVGu73eC9mE4_iKG17bFH-nJo4Cj-ShmMohRth_xQowaP6VLX9sc\\$>](https://urldefense.com/v3/_http://www.bundesgesundheitsministerium.de_!!DOxrgLBm!WBVrxOK16DCealygIMCVGu73eC9mE4_iKG17bFH-nJo4Cj-ShmMohRth_xQowaP6VLX9sc$>)

[www.twitter.com/BMG_Bund](https://twitter.com/BMG_Bund)

<[https://urldefense.com/v3/_http://www.twitter.com/BMG_Bund_!!DOxrgLBm!WBVrxOK16DCealygIMCVGu73eC9mE4_iKG17bFH-nJo4Cj-ShmMohRth_xQowaPtk9e7ns\\$>](https://urldefense.com/v3/_http://www.twitter.com/BMG_Bund_!!DOxrgLBm!WBVrxOK16DCealygIMCVGu73eC9mE4_iKG17bFH-nJo4Cj-ShmMohRth_xQowaPtk9e7ns$>)

www.facebook.com/BMG.Bund

<[https://urldefense.com/v3/_http://www.facebook.com/BMG.Bund_!!DOxrgLBm!WBVrxOK16DCealygIMCVGu73eC9mE4_iKG17bFH-nJo4Cj-ShmMohRth_xQowaPILwYTKU\\$>](https://urldefense.com/v3/_http://www.facebook.com/BMG.Bund_!!DOxrgLBm!WBVrxOK16DCealygIMCVGu73eC9mE4_iKG17bFH-nJo4Cj-ShmMohRth_xQowaPILwYTKU$>)

Hinweis zu externen Links: Auf Art und Umfang der übertragenen bzw. gespeicherten Daten hat das BMG keinen Einfluss.

Der Schutz Ihrer Daten ist uns wichtig. Nähere Informationen zum Umgang mit personenbezogenen Daten im BMG können Sie der Datenschutzerklärung auf <https://www.bundesgesundheitsministerium.de/datenschutz.html> <[https://urldefense.com/v3/_https://www.bundesgesundheitsministerium.de/datenschutz.html_!!DOxrgLBm!WBVrxOK16DCealygIMCVGu73eC9mE4_iKG17bFH-nJo4Cj-ShmMohRth_xQowaP4K7i2Ds\\$>](https://urldefense.com/v3/_https://www.bundesgesundheitsministerium.de/datenschutz.html_!!DOxrgLBm!WBVrxOK16DCealygIMCVGu73eC9mE4_iKG17bFH-nJo4Cj-ShmMohRth_xQowaP4K7i2Ds$>) entnehmen.

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com <https://urldefense.com/v3/_https://www.astrazeneca.com_!!DOxrgLBm!WBVrxOK16DCealygIMCVGu73eC9mE4_i

2740438

[KGI7bFH-nJo4Cj-ShmMohRth_xQowaPIIP2Jkc\\$>](#)

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com
<[https://urldefense.com/v3/https://www.astrazeneca.com/!!DOxrgLBm!UuqMQdWipys2XGF5YgVGYFt7uGhw-lwOUgyvvpdwjCc02oRC07TzyOMqxUdhbDwIJ6Qlvk\\$](https://urldefense.com/v3/https://www.astrazeneca.com/!!DOxrgLBm!UuqMQdWipys2XGF5YgVGYFt7uGhw-lwOUgyvvpdwjCc02oRC07TzyOMqxUdhbDwIJ6Qlvk$)>

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com <<https://www.astrazeneca.com>>

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.
This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com